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The Women’s Health Study trial previously reported no overall effect of low-dose aspirin (100mg every other day) on invasive
breast cancer over an average of 10 years of treatment. The present subgroup analyses further show no effects by tumour
characteristics at diagnosis, suggesting that low-dose aspirin has no preventive effect on breast cancer.
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Aspirin inhibits cyclooxygenase enzymes (COX-1 and -2) (DuBois,
2004). Cyclooxygenase 2 (COX-2) overexpression induces the
occurrence of mammary tumours in transgenic mice (Liu et al,
2001). Prostaglandin E2 that is generated from COX-2 over-
expression stimulates the expression of cytochrome P450 aroma-
tase, a key enzyme in local oestrogen production, and induces
angiogenesis (DuBois, 2004). Cyclooxygenase 2 overexpression
occurs in approximately 40% of invasive breast cancer, and is
more common in tumours with large size, lymph node metastasis,
a ductal type of histology, high histological grade, or negative
hormone receptor status (Ristimaki et al, 2002). Thus, the effect of
aspirin may be stronger in these subtypes of tumours.
In July 2005, the Women’s Health Study (WHS) reported overall
results from the only randomised trial of aspirin and cancer risk in
women (Cook et al, 2005). After an average of 10 years of treatment
and follow-up, low-dose aspirin (100mg every other day) had no
effect on risk of invasive breast cancer overall or by combined
hormone receptor status in 39876 women aged X45 years. In a
subgroup analysis, we evaluate whether low-dose aspirin might
reduce risk according to tumour characteristics at diagnosis.
MATERIALS AND METHODS
Study design
During 1992–1996, a total of 39876 women with no history of
cancer or cardiovascular disease were enrolled and randomised
into a 2 2 factorial design of low-dose aspirin (100mg every
other day, provided by the Bayer HealthCare, Leverkusen,
Germany) and vitamin E (600IU every other day, provided by
the Natural Source Vitamin E Association) for the primary
prevention of cancer and cardiovascular disease (Clinicaltrials.gov
identifier, NCT00000479). The methods of the study design have
been described in detail previously (Cook et al, 2005). Written
informed consent was obtained from each participant. The trial
was approved by the Human Subjects Committee at the Brigham
and Women’s Hospital and monitored by an external Data and
Safety Monitoring Board.
Annually, participants were sent monthly calendar packs
containing study medications, and questionnaires inquiring about
potential adverse effects, adherence to pill taking, and occurrence
of disease outcomes. Study medications and disease ascertainment
were continued in blinded fashion through the scheduled end of
the trial (31 March 2004). Deaths of participants were identified by
reports from family members, postal authorities, and a search of
the National Death Index. Morbidity and mortality follow-up were
97.2 and 99.4% complete, respectively (Cook et al, 2005).
For reported diagnoses of breast cancer, medical records and
other relevant information were sought and reviewed by physi-
cians who were blinded to randomised treatment assignment for
final confirmation. Tumour characteristics at diagnosis were also
recorded from medical records. Only confirmed breast cancer
cases were included in the analysis. Women who had in situ breast
cancer and were diagnosed with a new invasive breast cancer at a
later date (13 cases) were counted as events in both analyses of in
situ and invasive cancers.
Statistical analysis
Analyses used the intent-to-treat principle. The hazard ratios
(HRs) and 95% confidence intervals (CIs) of breast cancer
comparing women randomised to low-dose aspirin vs placebo
according to tumour characteristics were computed by Cox
proportional hazards regression models with adjustments for age
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y(in years) and randomised treatment assignments of vitamin E
(vitamin E vs placebo) and b-carotene (b-carotene vs placebo). The
proportionality assumption was tested by including an interaction
term of aspirin with the logarithm of time and was not violated for
total (P-value¼0.78), invasive (P-value¼0.87), or in situ breast
cancer (P-value¼0.27).
SAS version 9.1 (SAS Institute, Cary, NC, USA) was used for all
analyses. All P-values were two-sided at the significance level of
p0.05.
RESULTS
Low-dose aspirin treatment had no significant effect on risk of
total (762 vs 779 cases, HR¼0. 98, 95% CI: 0.88–1.08), invasive
(608 vs 622 cases, HR¼0.98, 95% CI: 0.87–1.09) (Cook et al,
2005), or in situ breast cancers (159 vs 165 cases, HR¼0.96, 95%
CI: 0.78–1.20). Similarly, there were no significant effects of low-
dose aspirin on risk of invasive breast cancer according to tumour
size, histology, or histologic grading and differentiation (Table 1).
However, there appeared a borderline significant increase in risk
for tumours with unknown size or metastasised to lymph nodes.
In addition, there was no significant effect of low-dose aspirin
according to either oestrogen receptor (ER) or progesterone
receptor (PR) status (Table 1), or the combined ER and PR status
(Cook et al, 2005).
DISCUSSION
In this large randomised trial, an average of 10 years of treatment
with low-dose aspirin (100mg on alternate days) did not affect
breast cancer risk overall or by tumour characteristics at diagnosis.
The results from the few studies by breast tumour characteristics
are conflicting. In a case–control study, aspirin use was associated
with a decreased risk for hormone receptor-positive tumours, but
not for hormone receptor-negative tumours (Terry et al, 2004). By
contrast, in the California Teachers Study cohort, daily long-term
use of aspirin was not associated with risk for ERþ/PRþ breast
cancer, but with a significantly increased risk for ER /PR  breast
cancer (Marshall et al, 2005). Also, no association was observed for
either localised or unlocalised breast tumours. In the Multiethnic
Cohort, duration of aspirin use was not associated with risk of
breast tumours positive for ER and/or PR or negative for both (Gill
Table 1 Hazard ratios of invasive breast cancer according to randomised aspirin treatment, by tumour characteristics in the Women’s Health Study
Aspirin Placebo Hazard ratio
Variable (n¼19934) (n¼19942) (95% CI) P-value
Invasive breast cancer – no. of cases 608 622 0.98 (0.87, 1.09) 0.68
Tumour size
p2cm 436 457 0.95 (0.84, 1.09) 0.48
42–5cm 129 126 1.02 (0.80, 1.31) 0.86
45cm 12 18 0.67 (0.32, 1.39) 0.28
Any size with direct extension to chest wall or skin 2 4 0.50 (0.09, 2.73) 0.42
Missing 29 17 1.71 (0.94, 3.10) 0.08
Lymph nodes
No metastasis 415 453 0.92 (0.80, 1.05) 0.19
Metastasis to lymph nodes 163 134 1.22 (0.97, 1.53) 0.09
Missing 30 35 0.86 (0.53, 1.39) 0.53
Histology
Duct carcinoma 438 452 0.97 (0.85, 1.10) 0.63
Lobular carcinoma 64 76 0.84 (0.60, 1.17) 0.31
Duct and lobular carcinoma 54 45 1.20 (0.81, 1.78) 0.37
Adenocarcinoma 3 5 0.60 (0.14, 2.52) 0.49
Tubular adenocarcinoma 13 19 0.68 (0.34, 1.39) 0.29
Mucinous adenocarcinoma 14 11 1.27 (0.58, 2.79) 0.56
Medullary carcinoma 4 4 1.00 (0.25, 4.00) 40.99
Other 18 10 1.80 (0.83, 3.90) 0.14
Histologic grading and differentiation
Well differentiated 127 147 0.86 (0.68, 1.10) 0.22
Moderately differentiated 249 253 0.98 (0.83, 1.17) 0.85
Poorly differentiated/anaplastic 150 143 1.05 (0.83, 1.32) 0.68
Missing 82 79 1.04 (0.76, 1.41) 0.82
Oestrogen receptor status
Positive 473 496 0.95 (0.84, 1.08) 0.45
Negative 101 100 1.01 (0.77, 1.33) 0.94
Borderline 5 1 5.00 (0.59, 42.8) 0.14
Missing 29 25 1.16 (0.68, 1.98) 0.59
Progesterone receptor status
Positive 421 428 0.98 (0.86, 1.12) 0.80
Negative 147 155 0.95 (0.76, 1.19) 0.65
Borderline 5 3 1.66 (0.40, 6.96) 0.49
Missing 35 36 0.97 (0.61, 1.55) 0.91
CI, confidence interval.
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yet al, 2007). In the WHS trial, besides a lack of effect according to
ER and PR status, there were no significant effects of low-dose
aspirin by tumour size, lymph node metastasis, histology, or
histologic grading and differentiation. The borderline significant
results for tumours with unknown size or metastasised to lymph
nodes were likely a result of chance. Taken together, the current
data do not provide evidence for an association of aspirin use with
risk of breast cancer by tumour characteristics.
Strengths of this study include a randomised, double-blind,
placebo-controlled design, which minimises the confounding and
biases that potentially affect observational studies, and the results
cannot readily be explained by inadequate duration of treatment
and follow-up.
The possibility remains that our lack of effect of aspirin might
be due to inadequate dose. However, in colorectal tissues, daily
40.5, 81, 325, and 650mg doses of aspirin have a similar inhibitory
effect on the production of prostaglandins (Ruffin et al, 1997). The
results from observational studies by aspirin doses are far from
consistent. In the Women’s Health Initiative cohort, only regular-
dose (325mg) aspirin, but not low-dose (81mg) aspirin, was
associated with a reduced risk of breast cancer (Harris et al, 2003).
In a study using a Canadian automated database, there was no
association for frequent use of aspirin at a dose of p100mgday
 1,
but an inverse association at a dose of 4100mgday
 1 (Rahme
et al, 2005). By contrast, in the UK General Practice Research
Database, a significant reduction was seen only for a daily 75mg
dose, but not for daily doses of 150 and 300mg (Garcia Rodriguez
and Gonzalez-Perez, 2004). Furthermore, the Vitamins and Life-
style Study reported a significantly reduced risk with the use of
low-dose aspirin at X4 daysweek
 1 over 10 years, whereas an
increased risk with frequent use of regular or extra strength aspirin
(Ready et al, 2007).
In summary, findings from this large randomised trial do not
provide support for the use of low-dose aspirin as a chemo-
preventive agent for breast cancer.
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